Article Text

other Versions

A new advanced glycation inhibitor LR-90 prevents experimental diabetic retinopathy in rats
  1. Ashay D Bhatwadekar (abhatwadekar01{at},
  2. Josephine V Glenn (j.v.glenn{at},
  3. James L Figarola (jlfigarola{at},
  4. Stephen Scott (sscott{at},
  5. Tom A Gardiner (t.gardiner{at},
  6. Samuel Rahbar (srahbar{at},
  7. Alan W Stitt (a.stitt{at}
  1. Queen's University Belfast, United Kingdom
  2. Queen' S University Belfast, United Kingdom
  3. City of Hope National Medical Centre, United States
  4. City of Hope National Medical Centre, United States
  5. Queens University-Belfast, United Kingdom
  6. City of Hope National Medical Center and Beckman Research Institute,, United States
  7. The Queen's University of Belfast, United Kingdom


    Background/Aims: Diabetic retinopathy is associated with accumulation of advanced glycation end products (AGEs) in the retinal microvasculature. LR-90 is an effective multistage inhibitor of advanced glycation with renoprotective and anti-inflammatory properties. In the present study we have explored the role of LR-90 in the progression of experimental diabetic retinopathy.

    Methods: Streptozotocin (STZ) induced diabetic Sprague-Dawley rats were treated with LR-90 (50mg/l in drinking water) for up to 32 weeks. At the end of the study eyes were enucleated and subjected to trypsin digestion and staining with light green-haematoxylin. Acellular capillaries and number of pericytes were quantified in random fields using light microscopy.

    Results: In the LR-90 treated diabetic animals, acellular capillary numbers were reduced to 1.63 ± 0.20 from 2.58 ± 0.49 (p<0.05) in diabetic controls. Also, LR-90 treatment significantly restored pericyte deficit from 18.12 ± 0.98 in diabetic rats to 24.19 ± 0.76 (p<0.001) in the LR-90 treated group. Conclusion: These findings demonstrate that LR-90 can effectively inhibit important lesions of diabetic retinopathy. This agent has potential for preventing retinopathy in diabetic patients.

    • Advanced Glycation End Products
    • Diabetic retinopathy
    • LR-90

    Statistics from

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.